Apple cider vinegar for diabetes and glycemia: what clinical studies say 2026

For joint pain and reflux, the evidence for the effectiveness of apple cider vinegar (ACV) is weak or conflicting. With diabetes and glycemia, the story is different – and worth noting. Randomized clinical trials have shown that ACV taken before a carbohydrate-rich meal actually lowers postprandial glycemia by 20–34% in individuals with insulin resistance and type 2 diabetes. This is not anecdotal, but the result of controlled experiments with reproducible outcomes. At the same time, ACV is not a diabetes cure – it does not replace metformin, a diabetic diet, or regular physical activity. This article will explain what studies have shown, how the mechanism works, how to safely use ACV, and when medical consultation is needed.

KEY INFORMATION
• Johnston et al. (Diabetes Care, 2004) – a primary clinical study: 20 ml of ACV before meals reduced postprandial glycemia by 19–34% in individuals with insulin resistance and type 2 diabetes.
• Johnston et al. (Annals of Nutrition and Metabolism, 2010) confirmed the effect and showed a reduction in fasting glycemia by 4–6% after 12 weeks of ACV use.
• Mechanism: acetic acid inhibits alpha-amylase (starch digestion), slows gastric emptying, and increases glucose uptake by muscles.
• Note: ACV + hypoglycemic medications = risk of hypoglycemia. Medical consultation is necessary.

Badania Johnstona – fundament naukowy ACV i glikemii

Two studies by Carol Johnston's group from Arizona State University are key to understanding the effect of ACV on glycemia. Johnston et al. (Diabetes Care, 2004) This is the first and most cited. The study involved 29 participants divided into three groups: healthy volunteers, individuals with insulin resistance (pre-diabetes), and individuals with type 2 diabetes. Protocol: 20 ml of ACV or placebo (water with lemon juice) consumed just before a meal consisting of white bread (50 g of carbohydrates). Glycemia was measured 30 and 60 minutes after the meal.

The results were convincing: in individuals with insulin resistance, ACV reduced postprandial glycemia by 34% compared to placebo. In individuals with type 2 diabetes – by 19%. In healthy volunteers, the effect was statistically insignificant. At the same time, the insulin index (insulin concentration after the meal) was 9–34% lower with ACV – suggesting that not only does glycemia decrease, but the burden on the pancreas is also reduced.

Johnston et al. (Annals of Nutrition and Metabolism, 2010) They extended the study to 12 weeks and demonstrated that regular use of ACV (2 tablespoons in a glass of water before the main meal) lowered fasting glucose levels by 4–6% in individuals with type 2 diabetes. This is a smaller effect than postprandial, but clinically significant for those with morning hyperglycemia.

Our observations: The 34% reduction in postprandial glycemia by ACV sounds impressive, but it requires context. The starting point was a meal consisting of white bread (glycemic index around 75), which itself causes a strong sugar spike. ACV "balanced" this glycemic response, but with a low-glycemic, minimally processed diet, the effects of ACV would be much smaller – because the starting point for reduction is lower. If the diet is already good, ACV provides a smaller marginal gain than when consuming white bread.

How does ACV work on glucose – how does it work?

Acetic acid from ACV lowers postprandial glycemia through at least three mechanisms that complement each other. Each of them has separate support in the scientific literature.

Hamowanie alfa-amylazy: Alpha-amylase is a salivary and pancreatic enzyme that breaks down starch into simple sugars. Acetic acid inhibits its activity, slowing down the digestion of complex carbohydrates into glucose. Shishehbor et al. (European Journal of Clinical Nutrition, 2008) They demonstrated that acetic acid clearly inhibits alpha-amylase and alpha-glucosidase (the second starch digestion enzyme) activity in vitro, which translates to a slower increase in glycemia after a meal.

Slowing gastric emptying: Acetic acid slows the passage of food from the stomach to the small intestine, which prolongs the absorption of glucose. This effect, known from studies Liljeberg i Bjorck (European Journal of Clinical Nutrition, 1998), explains the "flattening" of the glycemic curve after a meal with vinegar. Note: this same slowing may exacerbate symptoms in individuals with gastroparesis (delayed gastric emptying), which is a common complication of diabetes. People with gastroparesis should avoid ACV.

Increased glucose uptake by muscles: Acetic acid activates AMPK (AMP-activated protein kinase) – the cellular "energy sensor" that increases glucose uptake by muscles independently of insulin. Fushimi et al. (British Journal of Nutrition, 2006) They demonstrated this mechanism in studies on mice. In humans, AMPK activation by ACV is likely, although direct measurements in diabetic patients are limited.

How to use ACV for diabetes – a research-based protocol

The protocol for using ACV in clinical studies has been consistent: 15–30 ml (1–2 tablespoons) of ACV diluted in 40–100 ml of water, consumed just before the main carbohydrate-rich meal (breakfast or lunch). It is crucial to drink it before the meal, not during or after – the effect of inhibiting amylase and slowing gastric emptying depends on the presence of acetic acid in the stomach at the time food arrives.

For type 2 diabetes and regular use of ACV, a sensible practice is: start with 1 tablespoon (15 ml) for the first week, monitor glycemia before and after meals using a glucometer. If you see a more pronounced drop than usual – check if it causes hypoglycemia in the hours after the meal. After a week, if there is no hypoglycemia, you can increase to 2 tablespoons (30 ml). Always dilute, use a straw, rinse your mouth.

An important practical issue: ACV is not equally effective with all types of meals. The strongest glycemic effect has been shown with meals containing refined carbohydrates (white bread, white rice, pasta, potatoes). With meals that have a low glycemic index (vegetables, legumes, whole grains, meat with non-starchy vegetables), the effect is significantly weaker or negligible, as the glycemic response is itself subdued and there is no large "spike" to suppress. Therefore, ACV makes the most sense with typical Polish breakfasts with bread or lunches based on white rice or potatoes.

ACV interactions with diabetes medications – critical warning

Individuals treated pharmacologically for diabetes must exercise particular caution when using ACV. The additive effect of lowering glycemia can lead to hypoglycemia – which is potentially dangerous in insulin-treated diabetes. The most important scenarios:

Insulina: ACV lowers postprandial glycemia by 19–34%. If insulin is simultaneously administered based on the "standard" glycemic curve, the combination may cause an excessive drop in sugar. Monitoring glycemia and possible insulin dose adjustment with a diabetologist is necessary.

Metformina: The main medication for type 2 diabetes works by inhibiting hepatic gluconeogenesis and increasing insulin sensitivity. ACV and metformin do not have identical mechanisms, but they lower glycemia synergistically. The risk of hypoglycemia is lower than with insulin, but monitoring glycemia after introducing ACV is sensible for the first 2–4 weeks.

Pochodne sulfonylomocznika (gliklazyd, glimepiryda): These medications stimulate the pancreas to secrete insulin regardless of glycemia – which makes them particularly prone to hypoglycemia when combined with ACV. Consultation with a diabetologist is mandatory.

Remember: never discontinue diabetes medications in favor of ACV or any other supplement without consulting a doctor. ACV is a complement to treatment, not a substitute.

Limitations of evidence and what is still unknown about ACV and diabetes

Enthusiasm for ACV in diabetes must be balanced with a fair assessment of the limitations of the research. First: most studies have small sample sizes (20–30 participants), which limits statistical power and the ability to generalize results. Second: studies are usually short-term (4–12 weeks) – there is a lack of data on long-term efficacy and safety beyond one year. Third: there is a lack of large, multicenter randomized studies with hard endpoints (reduction of HbA1c to clinically significant values, reduction of diabetes complications, reduction of cardiovascular events).

The effect on HbA1c – a key marker of diabetes control over 2–3 months – is poorly studied. Johnston et al. (2010) they did not show a statistically significant reduction in HbA1c with 12-week ACV supplementation, although the trend was in the right direction. This suggests that the effect of ACV on postprandial glycemia does not automatically translate into large improvements in long-term control. In comparison: metformin typically lowers HbA1c by 1–2% absolutely, which has a clear clinical impact. ACV does not compete in this regard.

It is also worth mentioning the type of ACV used in studies. Johnston and others used standard 5% acetic acid ACV – not special encapsulated supplements with standardized concentrations. ACV capsules that can be purchased as a supplement have variable bioavailability and different doses of active acetic acid – their effectiveness may be significantly lower than liquid ACV used according to the study protocol. Liquid ACV is more reliable in terms of replicating research effects.

ACV a pre-cukrzyca i profilaktyka cukrzycy

The 2004 Johnston study showed the strongest glycemic effect of ACV specifically in individuals with insulin resistance – that is, in the diabetes risk group, where the intervention has the greatest preventive potential. Insulin resistance (pre-diabetes, HbA1c 5.7–6.4%) affects an estimated WHO (2016) about 15% of the adult population in developed countries and without intervention often progresses to type 2 diabetes.

In the case of insulin resistance, ACV as part of an anti-insulin resistance diet has a biological rationale. However, the anti-insulin resistance diet primarily involves: reducing refined carbohydrates, avoiding sugar and sweetened beverages, regular exercise (especially strength training and HIIT), and normalizing weight and sleep. ACV can be a practical tool before meals with a higher glycemic index, acting as a "glycemic buffer." But without changes in diet and lifestyle, ACV will provide limited long-term benefits – it is a supportive tool, not an alternative to a healthy lifestyle.

For individuals diagnosed with insulin resistance, it is worth considering measuring fasting insulin, HOMA-IR, and a lipid profile to monitor the progress of the intervention – regardless of whether it includes ACV or not. Improvement in HOMA-IR (insulin resistance index) after 3–6 months is a good biomarker of the effectiveness of a comprehensive dietary and lifestyle intervention.

Comparing ACV with other supplements affecting glycemia: berberine (may lower glycemia comparably to metformin in some studies), cassia cinnamon (moderate effect mainly on fasting glycemia, risk of coumarin toxicity at high doses), chromium picolinate (supports insulin action in case of chromium deficiency), and soluble fiber (psyllium, inulin, beta-glucan from oats) have better-studied and often stronger effects on glucose metabolism than ACV. However, ACV is the cheapest, readily available, and has the simplest usage protocol – and uniquely has several randomized clinical trials directly confirming its effect on postprandial glycemia with a single dose.

Frequently Asked Questions

Does apple cider vinegar lower blood sugar levels?

Yes – it is one of the few effects of ACV with solid support from clinical research. Johnston et al. (Diabetes Care, 2004) They demonstrated a reduction in postprandial glycemia by 19–34% in cases of insulin resistance and type 2 diabetes. The effect is strongest with meals containing refined carbohydrates and requires drinking ACV directly before the meal.

How to use apple cider vinegar for diabetes?

20 ml (4 teaspoons) ACV diluted in 40–100 ml of water, consumed just before the main meal. Always dilute. Monitor blood glucose with a glucometer after introducing ACV. Consultation with a doctor is necessary when simultaneously treating with insulin or a sulfonylurea derivative (risk of hypoglycemia).

How much ACV should be taken for diabetes?

The study dose is 15–30 ml (1–2 tablespoons) daily, before meals. Start with 1 tablespoon (15 ml) for the first week, monitor blood glucose with a glucometer 1–2 hours after meals. Do not exceed 2 tablespoons without consulting a doctor. The Johnston study 2010 confirmed the safety of 2 tablespoons daily for 12 weeks without serious adverse effects. Encapsulated forms of ACV have lower and less predictable bioavailability – liquid ACV is closer to the study protocol.

Does ACV lower HbA1c?

The results are inconclusive. Johnston et al. (2010) did not show a statistically significant reduction in HbA1c over 12 weeks, although the effect on postprandial glucose was evident. Reducing HbA1c requires long-term, consistent action on daily glucose levels. ACV taken selectively before certain meals likely does not provide a sufficient cumulative effect on the daily glycemic curve to clinically change HbA1c. For the effect on HbA1c, a comprehensive low-glycemic diet and physical activity are more important.

Does ACV help with insulin resistance?

Johnston et al. (2004) They demonstrated the greatest effect of ACV specifically in this group – a 34% reduction in postprandial glucose. Mitrou et al. (European Journal of Clinical Nutrition, 2015) They confirmed improved insulin sensitivity in people with type 2 diabetes after ACV. ACV may be a valuable tool in insulin resistance as a complement to a low-glycemic diet and physical activity.

Can people with diabetes take ACV along with metformin?

Possible, but requires caution. Both lower blood glucose, which can have an additive effect. There are no direct studies on this combination. Monitoring blood glucose after introducing ACV and consulting with an endocrinologist is essential. Never stop taking metformin in favor of ACV – they work through different mechanisms, and ACV will not replace the medication.

Does ACV work for type 1 diabetes?

Studies on ACV in the context of diabetes have only concerned type 2 diabetes and insulin resistance. In type 1 diabetes (autoimmune, requiring insulin), the lack of pancreatic insulin production means that the mechanisms of action of ACV (improving insulin sensitivity, stimulating AMPK) are less or differently significant. People with type 1 diabetes using ACV must monitor blood glucose and adjust their insulin dose together with an endocrinologist – ACV may change the postprandial glucose profile and thus require adjustments to insulin boluses.

You can read more about the impact of apple cider vinegar on the digestive system and safe dosing in the article Apple cider vinegar for reflux and heartburn.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a physician, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04